Please assess the completion status of the following clinical trial:

Trial Title: EARly Prevention of aTHeroma Progression

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men or women at least 35 years of age~* Mild CAD (nonobstructive coronary atherosclerotic plaques, lumen narrowing \<50%) and CAC score \<300 in at least one segment of proximal or mid-portion of major epicardial coronary arteries~* LDL cholesterol \<130mg/dl~Exclusion Criteria:~* History of stable angina, or acute coronary syndrome~* History of transient ischemic attack, or stroke~* Chronic kidney disease (eGFR\< 60ml/min)~* Diabetes mellitus with microvascular complications or insulin therapy~* Hypertriglyceridemia (triglyceride \>500mg/dl)~* Any statin therapy in the past 4 weeks~* Planned cardiac surgery or planned major non-cardiac surgery within 6 months.~* Chronic disease requiring treatment with oral, intravenous, or intra-articular corticosteroids (use of topical, inhaled, or nasal corticosteroids is permissible).~* A diagnosis of cancer (other than superficial squamous or basal cell skin cancer) in the past 3 years or current treatment for the active cancer.~* Any clinically significant abnormality identified at the screening visit, physical examination, laboratory tests, or electrocardiogram which, in the judgment of the Investigator, would preclude safe completion of the study.~* Hepatic disease or biliary tract obstruction, or significant hepatic enzyme elevation (ALT or AST \> 3 times upper limit of normal).~* History of adult asthma manifested by bronchospasm in the past 6 months, or currently taking regular anti-asthmatic medication(s).~* Unwillingness or inability to comply with the procedures described in this protocol.~* Positive pregnancy test (all female subjects of childbearing potential must have a urine ß-human chorionic gonadotropin(hCG) pregnancy test performed at Screening and/ or within 7 days prior to randomization) or is known to be pregnant or lactating.~* Hypersensitivity to Crestor~* Skeletal muscle disease~* Combination use with cyclosporine~* Galactose intolerance, Lapp lactose deficiency or glucose-galactose malabsorption~* Combination use of protease inhibitor

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard Therapy (Type: ACTIVE_COMPARATOR): Risk factor control Diet Exercise
- Rosuvastatin therapy (Type: EXPERIMENTAL): Risk factor control Rosuvastatin

Based on this trial design, predict the completion outcome and termination type (if applicable).